Feng Yan

Feng Yan

Jiangsu Cancer Hospital & Nanjing Medical University Cancer Hospital, China

Title: Diagnostic and prognostic value of UHRF1 in breast cancer patients


Feng Yan, is the vice director of Department of Clinical Laboratory in Nanjing Medical University Cancer Hospital. The research works of Feng Yan focus on the bioanalytical chemistry in laboratory medical diagnostics, particularly in detection of tumor markers and tumor cells. She has published 74 papers in SCI journals.


Ubiquitin-like, containing PHD and RING finger domains 1 (UHRF1) has been reported to play an important role in breast carcinogenesis. This work investigated the correlation of UHRF1 DNA level in plasma with clinical characteristics of breast cancer and its clinical significance in breast cancer diagnosis. The expression of UHRF1 in primary breast cancer tissue was examined by western blot. The UHRF1 DNA levels in plasma and UHRF1 mRNA expression in tissues were determined by accurate real-time quantitative PCR. The associations of UHRF1 levels with clinical variables were evaluated using standard statistical methods. The UHRF1 DNA in plasma of 229 breast cancer patients showed higher expression than healthy controls, which showed high specificity up to 76.2% at a sensitivity of 79.2%, and was significantly associated with c-erbB2 positive status, cancer stage and lymph node metastasis. High UHRF1 DNA level in plasma was significantly associated with short progression-free survival. The UHRF1 DNA level in plasma is highly correlative with breast cancer and its status and stage, and may be a potential independent diagnostic and prognostic factor for both breast cancer and the survival of breast cancer patients.

Speaker Presentations

Speaker PDFs